BriaCell Therapeutics Corp.
BCTX
$2.02
-$0.05-2.42%
NASDAQ
| 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | 04/30/2024 | |
|---|---|---|---|---|---|
| Net Income | -19.43M | -11.59M | -16.60M | -4.79M | -6.00M |
| Total Depreciation and Amortization | 152.50K | 129.60K | 106.70K | 83.80K | 15.20K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -3.77M | -14.33M | -11.75M | -26.47M | -26.84M |
| Change in Net Operating Assets | -1.02M | 3.79M | 4.77M | 7.05M | 1.81M |
| Cash from Operations | -24.07M | -21.99M | -23.48M | -24.13M | -31.01M |
| Capital Expenditure | -456.80K | -456.80K | -456.80K | -456.80K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -255.00K | -375.00K | -300.00K | -225.00K | -225.00K |
| Cash from Investing | -711.80K | -831.80K | -756.80K | -681.80K | -225.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 36.31M | 21.60M | 16.38M | 4.42M | 4.00M |
| Repurchase of Common Stock | -- | -- | -- | -- | 0.00 |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 36.31M | 21.60M | 16.38M | 4.42M | 4.00M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.52M | -1.23M | -7.85M | -20.39M | -27.23M |